Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 8/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7050684 | 0.97 | KMT2A (0.34) | KMT2AMEN1PDE5APOLBMET | |
| SCHEMBL7053379 | 0.96 | PDE5A (0.36) | KMT2AMEN1PDE5APOLBMET | |
| SCHEMBL7053061 | 0.93 | PDE5A (0.35) | PDE5AMET | |
| SCHEMBL7053105 | 0.93 | PDE5A (0.34) | KMT2AMEN1PDE5APOLB | |
| SCHEMBL7053059 | 0.93 | KMT2A (0.38) | KMT2AMEN1PDE5APOLB | |
| SCHEMBL7054904 | 0.93 | PDE5A (0.39) | KMT2AMEN1PDE5APOLB | |
| SCHEMBL7057287 | 0.93 | KMT2A (0.39) | KMT2AMEN1PDE5APOLB | |
| SCHEMBL7117993 | 0.91 | PDE5A (0.33) | KMT2AMEN1PDE5AHDAC1HDAC2 | |
| SCHEMBL7056316 | 0.91 | KMT2A (0.35) | KMT2AMEN1PDE5APOLBMET | |
| SCHEMBL7049975 | 0.90 | PDE5A (0.39) | PDE5AMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171361-A1 | Pyrrolopyrimidinone derivatives, process of preparation and use | SK CHEMICALS CO., LTD. (KR) | 2003-09-11 | — | — | US | disclosed |
| EP-1303279-A1 | METHOD OF TREATING PERIPHERAL VASCULAR DISEASES, PERIPHERAL NEUROPATHIES, AND AUTONOMIC NEUROPATHIES | Wood, Ralph, E. (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002002118-A1 | METHOD OF TREATING PERIPHERAL VASCULAR DISEASES, PERIPHERAL NEUROPATHIES, AND AUTONOMIC NEUROPATHIES | WOOD RALPH E (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171361-A1 | Pyrrolopyrimidinone derivatives, process of preparation and use | CYP2C19, DHPS, SDHA | KMT2A 4373/4885MEN1 2829/4885PDE5A 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.